Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A.[ Read More ]
The intrinsic value of one PASG stock under the base case scenario is HIDDEN Compared to the current market price of 0.519 USD, Passage Bio, Inc. is HIDDEN
Current Assets | 118 M |
Cash & Short-Term Investments | 114 M |
Receivables | 0 |
Other Current Assets | 3.66 M |
Non-Current Assets | 32.6 M |
Long-Term Investments | 0 |
PP&E | 32.2 M |
Other Non-Current Assets | 433 K |
Current Liabilities | 16.3 M |
Accounts Payable | 1.3 M |
Short-Term Debt | 6.75 M |
Other Current Liabilities | 8.3 M |
Non-Current Liabilities | 22.9 M |
Long-Term Debt | 22.9 M |
Other Non-Current Liabilities | 0 |
Revenue | 0 |
Cost Of Revenue | 3.72 M |
Gross Profit | -3.72 M |
Operating Expenses | 108 M |
Operating Income | -108 M |
Other Expenses | -6.33 M |
Net Income | -102 M |
Net Income | -102 M |
Depreciation & Amortization | 3.72 M |
Capital Expenditures | -146 K |
Stock-Based Compensation | 10.9 M |
Change in Working Capital | 5.34 M |
Others | 11.9 M |
Free Cash Flow | -78.4 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 month ago
Sep 19, 2024
|
Sell 27.9 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
- 39300
|
0.71 USD |
2 months ago
Sep 16, 2024
|
Sell 46.7 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
- 63100
|
0.74 USD |
2 months ago
Sep 17, 2024
|
Sell 81.3 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
- 111400
|
0.73 USD |
1 month ago
Sep 18, 2024
|
Sell 18.7 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
- 25631
|
0.73 USD |
9 months ago
Feb 13, 2024
|
Sell 1.43 K USD
|
Borthwick Kathleen
SVP, INTERIM CFO |
- 1470
|
0.97 USD |
9 months ago
Feb 13, 2024
|
Sell 1.59 K USD
|
Forman Mark S
CHIEF MEDICAL OFFICER |
- 1638
|
0.97 USD |
10 months ago
Jan 02, 2024
|
Sell 14.4 K USD
|
Forman Mark S
Chief Medical Officer |
- 15813
|
0.91 USD |
10 months ago
Jan 02, 2024
|
Sell 9.71 K USD
|
Borthwick Kathleen
SVP, Interim CFO |
- 10672
|
0.91 USD |
10 months ago
Jan 02, 2024
|
Sell 14.4 K USD
|
Cale Edgar B.
GC & Corporate Secretary |
- 15813
|
0.91 USD |
1 year ago
Jul 28, 2023
|
Sell 10.1 K USD
|
King Simona
Chief Financial Officer |
- 11453
|
0.88 USD |
1 year ago
Jun 28, 2023
|
Bought 483 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 575195
|
0.84 USD |
1 year ago
Jun 27, 2023
|
Bought 519 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 617382
|
0.84 USD |
1 year ago
Jun 16, 2023
|
Sell 3.78 K USD
|
Fotopoulos Alexandros
Chief Technical Officer |
- 4052
|
0.9325 USD |
1 year ago
Apr 18, 2023
|
Sell 2.16 K USD
|
King Simona
Chief Financial Officer |
- 2053
|
1.05 USD |
1 year ago
Dec 01, 2022
|
Sell 5.96 K USD
|
Kapadia Sandip
Director |
- 5000
|
1.1929 USD |
1 year ago
Nov 22, 2022
|
Sell 4.95 K USD
|
Fotopoulos Alexandros
Chief Technical Officer |
- 3720
|
1.33 USD |
2 years ago
Sep 19, 2022
|
Sell 2.54 K USD
|
Toernsen Monika Maria
Chief Commercial Officer |
- 1681
|
1.5105 USD |
2 years ago
May 04, 2022
|
Bought 589 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 303500
|
1.94 USD |
2 years ago
May 03, 2022
|
Bought 427 K USD
|
OrbiMed Capital GP VII LLC
director: |
+ 221500
|
1.93 USD |
2 years ago
May 03, 2022
|
Bought 427 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 221500
|
1.93 USD |
2 years ago
Jan 20, 2022
|
Bought 254 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 50800
|
5 USD |
2 years ago
Mar 21, 2022
|
Bought 31.5 K USD
|
Goldsmith Bruce A
CEO and President |
+ 10000
|
3.15 USD |
2 years ago
Jan 20, 2022
|
Bought 2 M USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 369100
|
5.42 USD |
2 years ago
Jan 19, 2022
|
Bought 221 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 43300
|
5.11 USD |
2 years ago
Jan 18, 2022
|
Bought 626 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 114700
|
5.46 USD |
2 years ago
Jan 14, 2022
|
Bought 57.7 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 10300
|
5.6 USD |
2 years ago
Jan 13, 2022
|
Bought 231 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 41800
|
5.52 USD |
2 years ago
Jan 12, 2022
|
Bought 565 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 100000
|
5.65 USD |
2 years ago
Jan 11, 2022
|
Bought 45.3 K USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 8200
|
5.53 USD |
3 years ago
May 21, 2021
|
Bought 30 K USD
|
Morris Richard Steven
Chief Financial Officer |
+ 2171
|
13.8183 USD |
3 years ago
May 21, 2021
|
Bought 26.2 K USD
|
Goldsmith Bruce A
CEO and President |
+ 2000
|
13.115 USD |
3 years ago
Mar 15, 2021
|
Sell 176 K USD
|
Romano Gary
Chief Medical Officer |
- 8383
|
20.9546 USD |
3 years ago
Mar 15, 2021
|
Sell 35.4 K USD
|
Romano Gary
Chief Medical Officer |
- 1617
|
21.8616 USD |
3 years ago
Jan 20, 2021
|
Sell 39 K USD
|
Quigley Jill M.
Chief Operating Officer |
- 1300
|
30.0085 USD |
3 years ago
Jan 14, 2021
|
Sell 491 K USD
|
Quigley Jill M.
Chief Operating Officer |
- 16298
|
30.1 USD |
4 years ago
Mar 24, 2020
|
Bought 150 K USD
|
Countouriotis Athena
Director |
+ 10000
|
14.975 USD |
4 years ago
Mar 03, 2020
|
Bought 9.9 M USD
|
Ratcliffe Liam
Director |
+ 550000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 50.4 K USD
|
Ratcliffe Liam
Director |
+ 2800
|
18 USD |
4 years ago
Feb 28, 2020
|
Bought 6.72 M USD
|
ORBIMED ADVISORS LLC
10 percent owner |
+ 373300
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 4.05 M USD
|
Versant Venture Capital VI, L.P.
10 percent owner |
+ 225000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 9.9 M USD
|
Frazier Life Sciences IX, L.P.
10 percent owner |
+ 550000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 4.05 M USD
|
Woiwode Thomas
director, 10 percent owner: |
+ 225000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 9.9 M USD
|
Heron Patrick J
director, 10 percent owner: |
+ 550000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 117 K USD
|
Yamada Tadataka
Director |
+ 6500
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 50.4 K USD
|
Ratcliffe Liam
Director |
+ 2800
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 27 K USD
|
Quigley Jill M.
Chief Operating Officer |
+ 1500
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 18 K USD
|
Quigley Jill M.
Chief Operating Officer |
+ 1000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 7.2 K USD
|
Morris Richard Steven
Chief Financial Officer |
+ 400
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 90 K USD
|
Kapadia Sandip
Director |
+ 5000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 90 K USD
|
Islam Saqib
Director |
+ 5000
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 19.8 K USD
|
Goldsmith Bruce A
CEO and President |
+ 1100
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 99 K USD
|
Fotopoulos Alexandros
Chief Technical Officer |
+ 5500
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 160 K USD
|
Countouriotis Athena
Director |
+ 8900
|
18 USD |
4 years ago
Mar 03, 2020
|
Bought 36 K USD
|
Cale Edgar B.
GC and Corporate Secretary |
+ 2000
|
18 USD |